The year 2023 will be an important year for the rapid development of life science in China

How do I understand the life sciences

Life science studies the origin and evolution of all life in nature, growth and development, genetic variation and other laws of life activities and the nature of life phenomena, as well as the interconnections and relations between various organisms, organisms and the environment. The field of life science research is actually much broader than these four words, such as what is the biological basis of basic and clinical medicine, cognitive science and artificial intelligence biological basis, and so on. Life science is not only a living life, but also directly related to our artificial intelligence calculation, and even artificial synthesis of new living bodies.

At present, the field of biomedicine is developing rapidly, and new technologies are emerging in an endless stream. In the research stage, there are many steps in drug target discovery, target selection, antigen preparation, drug candidate screening and function identification. During the whole research process, there is a large demand for biological reagents, consumables and experimental equipment, and it will play a role in promoting the related industry. At the same time, the employment prospects of biological professionals are broad, and the demand for scientific research personnel and technical personnel in enterprises is large.

How will Life Sciences change 2022?

The COVID-19 outbreak in 2022 has affected the operation and development of the global economy. The emergence, mutation, transmission, changes in pathogenicity, and effects on the human body all have a life science and medical basis, which can serve as a scientific and medical basis for us to timely adjust protective strategies as the virus changes. From this perspective, it also shows the strategic importance of life science research.

Combined with my own research field, today's intelligent technology has become a very important technical field in our future. With the increase of research on brain science, brain-like intelligent technology and artificial intelligence technology in China, it has a considerable role in promoting the research and development of the diagnosis and treatment technology of some brain diseases that have caused a great social burden for a long time.

At the same time, from the perspective of capital investment, the global life science research investment in 2022, according to incomplete statistics, the global scope reached 170 billion US dollars, the United States accounted for nearly half, China is about 120 billion yuan, maintaining a growing trend.

In 2022, China's biomedical industry will develop steadily. In 2022, global mergers and acquisitions in the life sciences and pharmaceutical sectors were unusually active, reaching $410 billion. It was also a more active year for China's M&A market, accounting for about $25 billion, or 6% of the world's total, and Amgen's $2.7 billion stake in Beigene was the largest merger in China's pharmaceutical and life sciences sector.

How will the Life Sciences impact 2023?

In 2023, life science research and development will continue to be a key area of scientific and technological development, and related research and development achievements in biomedical, biomedical engineering, synthetic biotechnology, intelligent technology and other technical fields will continue to appear and transform the landing.

The development trend that deserves attention is the rapid and high-quality development of China's life science industry. At present, the world's leading life science industry upstream enterprises are mainly concentrated in Europe, the United States and Japan and other developed countries, some Chinese enterprises after years of accumulation, gradually formed a core patent, can compete with the international leading enterprises in the market new entrants, 2023 will be an important year for the development of China's biomedical, biomedical engineering enterprises, will also be a key area of investment and financing.